VIVIMEDLAB — Vivimed Labs Income Statement
0.000.00%
- IN₹504.95m
- IN₹4.40bn
- IN₹699.89m
Annual income statement for Vivimed Labs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Preliminary |
| Revenue | |||||
| Total Revenue | 2,373 | 1,871 | 1,491 | 1,163 | 700 |
| Cost of Revenue | |||||
| Gross Profit | 580 | -1,145 | 619 | 564 | -37.6 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2,636 | 4,824 | 1,742 | 1,495 | 2,485 |
| Operating Profit | -263 | -2,953 | -251 | -333 | -1,785 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -648 | -3,307 | -458 | -318 | -1,763 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -677 | -3,285 | -454 | -321 | -1,765 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -677 | -3,285 | -454 | -321 | -1,765 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -677 | -3,285 | -454 | -320 | -1,765 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -8.16 | -32.6 | -3.37 | -3.85 | -21.1 |